News and Press Releases
Mogrify appoints Dr Jonathan Appleby as chief scientific officer
Strategic hire bolsters executive leadership team as company progresses multiple therapeutic programmes toward and into clinical development 15 July 2024 – Cambridge, UK – Mogrify, a regenerative medicine company developing...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: July 15, 2024
Elemental Machines Expands European Presence and Enhances AI-Predicted Health Score
27 June 2024 -- Florence, Italy -- Elemental Machines, a leader in smart lab and manufacturing connectivity solutions, is pleased to announce they are consolidating their position in the EU...
Category: BioManufacturing, Pharmaceutical
Posted: June 27, 2024
WCG and MRCT Center Form Task Force to Tackle Ethical Challenges in AI-Based Clinical Research
26 June 2024 -- New Jersey, US -- WCG, the global leader in providing solutions that measurably improve and accelerate clinical research, and the Multi-Regional Clinical Trials Center of Brigham...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 26, 2024
Avallano Strengthens Leadership with New Chief Strategy Officer to Drive AI-Powered Clinical Research Innovation
26 June 2024 -- South Carolina, US -- Avallano, an AI-enabled clinical research company, today announced the appointment of Michael A Ibara PharmD, as chief strategy officer (CSO). Dr Ibara...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 26, 2024
Basecamp Research launches ZymCTRL a world-first, open source, generative AI tool that designs enzymes for more sustainable industrial processes. ZymCTRL is the world’s first open-source, text-based enzyme generation model and can be used across multiple industries, including therapeutics and sustainability initiatives.
AI model able to produce sequences that produced functional enzymes with desirable characteristicsfor industrial applications. Basecamp Research field scientists collect samples during an expedition to Costa Rica on July 29,...
Category: BioManufacturing, Drug Delivery, Drug Discovery, Other
Posted: June 18, 2024
CluePoints Continues ‘Turning Artificial Intelligence into Human Intelligence’ by Launching Two New Innovations
Site Profile & Oversight Tool (SPOT) and Intelligent Medical Coding (IMC) unveiled by RBQM innovator at DIA Global Annual Meeting 2024 17 June 2024 -- Pennsylvania, US -- CluePoints, provider...
Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: June 17, 2024
Formycon reports on the results of the annual general meeting
Management provides detailed report on financial year 2023 and current company performance. Shareholders approve all agenda items and formally approve the acts of the members of the management board and...
Category: BioManufacturing
Posted: June 13, 2024
Deep Genomics Expands Executive Leadership and Operations in Latest Strategic Growth Initiative
Company announces executive new hires and marks significant momentum with Cambridge, Massachusetts, US, site opening and Toronto, Canada, office expansion 13 June 2024 -- Massachusetts, US -- Deep Genomics, the...
Category: Biotechnology, Other, Pharmaceutical
Posted: June 13, 2024
480 University Ave, Suite 1300 Toronto, Ontario, Canada, M5G 1V2
CluePoints, a leading provider of AI-driven software solutions for Clinical Data Review, receives significant investment for continued growth from EQT
CluePoints is a cloud-based software platform for Risk-Based Quality Management (RBQM) and data quality oversight in clinical trials, designed to enable safer and more efficient processes and improving data integrity...
Category: Biotechnology, Clinical Trials
Posted: June 12, 2024
CluePoints Brand Evolution Confirms Commitment to ‘Turning Artificial Intelligence into Human Intelligence’
CluePoints extends its use of AI/ML and continues to find smarter ways to manage clinical trials 11 June 2024 -- Pennsylvania, US -- CluePoints, provider of leading statistical and AI-driven...
Category: Clinical Trials, Other, Pharmaceutical
Posted: June 11, 2024
Biogen Receives European Commission Approval for QALSODY (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
SOD1-ALS is a devastating, uniformly fatal and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe QALSODY is Biogen’s third rare disease therapy to be...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 30, 2024
Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA
Exploring advanced technologies to help bring novel therapies to patients faster Sartorius to leverage NVIDIA solutions used in live-cell imaging platforms in drug discovery, predictive design of manufacturing processes and...
Category: Biotechnology, Drug Discovery
Posted: May 16, 2024
Sartorius Corporation, Otto-Brenner-Straße 20, 37079 Goettingen, Germany
Pharma and Regulatory Giants Tackle AI Trust and Legislative Challenges at Largest Ever Pistoia Alliance Annual Conference
Survey of life sciences experts found 70% recognise potential for AI, but many are struggling to get started or implement it at scale due to challenges including data integrity and...
Category: Clinical Trials, Logistics
Posted: May 8, 2024
Andaman7 Launches AI Supercharged Personal Health Record v5
New advanced AI simplification, summarisation and translation features empower patients and improve communication with healthcare providers and researchers 4 April 2024 -- Liège, Belgium -- Andaman7, the free app transforming...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: April 4, 2024
TMC Pharma champions holistic approach to medical services in rare disease drug development
13 March 2024 – In a recent webinar, rare disease specialist and global clinical research organisation (CRO) TMC Pharma gathered esteemed speakers to share insights into the scope of medical...
Category: Drug Discovery, Pharmaceutical
Posted: March 13, 2024
Lodge Farm Barn Elvetham Park Estate, Fleet Road, Hartley Wintney, Hampshire RG27 8AS, UK
